Case number 1:22-cv-00089
Otsuka Pharmaceutical Co., Ltd. et al v. Mylan Laboratories Limited et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 7, 2023 | 22 | ORDER OF DISMISSAL. This action is DISMISSED WITHOUT PREJUDICE and STRICKEN from the Court's active docket. Signed by Chief District Judge Thomas S Kleeh on 3/7/2023. (snc) (Entered: 03/07/2023) (1) |
| Mar 7, 2023 | 23 | REPORT to USPTO on the filing or determination of an action regarding re 22 Order Dismissing Case. (snc) (Entered: 03/07/2023) (1) |
| Mar 6, 2023 | 21 | STIPULATION of Dismissal by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Higginbotham, Daniel) (Entered: 03/06/2023) (2) |
| Feb 13, 2023 | 20 | STIPULATION by Mylan Pharmaceuticals Inc., Viatris Inc.. (O'Brien, William) (Entered: 02/13/2023) (3) |
| Jan 28, 2023 | 19 | STIPULATION Extending Time to Answer or Otherwise Respond to Complaint by Mylan Pharmaceuticals Inc., Viatris Inc.. (O'Brien, William) (Entered: 01/28/2023) (2) |
| Jan 27, 2023 | 18 | REPLY to Response to Motion re 13 MOTION to Stay Case filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit Proposed Order Granting Motion to Stay)(Higginbotham, Daniel) (Entered: 01/27/2023) (Main Document) (3) |
| Jan 27, 2023 | 18 | REPLY to Response to Motion re 13 MOTION to Stay Case filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Exhibit Proposed Order Granting Motion to Stay)(Higginbotham, Daniel) (Entered: 01/27/2023) (Exhibit Proposed Order Granting Motion to Stay) (2) |
| Jan 25, 2023 | 17 | Memorandum in Opposition re 13 MOTION to Stay Case Defendants Mylan Pharmaceuticals Inc.s, Mylan Laboratories Limiteds, and Viatris Inc.s Opposition to Plaintiffs Motion to Stay filed by Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc.. (Copland, Gordon) (Entered: 01/25/2023) (4) |
| Jan 20, 2023 | 16 | ORDER granting 14 Motion of Jeanette M. Roorda for Leave to Appear Pro Hac Vice on behalf of H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. Signed by Chief District Judge Thomas S Kleeh on 1/20/2023. (dk) (Entered: 01/20/2023) (1) |
| Jan 19, 2023 | 14 | MOTION for Leave to Appear Pro Hac Vice of Jeanette Roorda by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Proposed Order)(Higginbotham, Daniel) (Entered: 01/19/2023) (Main Document) (4) |
| Jan 19, 2023 | 15 | Pro Hac Vice Filing fee paid on behalf of Jeanette Roorda: $ 200.00, receipt number WVNC003581. (dk) (Entered: 01/19/2023) (0) |
| Jan 19, 2023 | 14 | MOTION for Leave to Appear Pro Hac Vice of Jeanette Roorda by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Attachments: # 1 Proposed Order)(Higginbotham, Daniel) (Entered: 01/19/2023) (Proposed Order) (1) |
| Jan 11, 2023 | 13 | MOTION to Stay Case by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd.. (Higginbotham, Daniel) (Entered: 01/11/2023) (3) |
| Jan 4, 2023 | 12 | FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING CONFERENCE:***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htmRule 26 Meeting to be held by 2/3/2023. Rule 26 Meeting Report due by 2/17/2023. Discovery due by 3/6/2023. Signed by Chief District Judge Thomas S Kleeh on 1/04/2023. (jb) (Entered: 01/04/2023) (6) |
| Dec 30, 2022 | 11 | NOTICE of Appearance by Brandon M. White on behalf of All Defendants (White, Brandon) (Entered: 12/30/2022) (2) |
| Dec 20, 2022 | 10 | STIPULATION Extending Time to Answer or Otherwise Respond to Complaint by Mylan Pharmaceuticals Inc., Viatris Inc.. (O'Brien, William) (Entered: 12/20/2022) (2) |
| Dec 13, 2022 | 8 | SUMMONS Returned Executed as to Mylan Pharmaceuticals Inc. served on 12/8/2022. (Higginbotham, Daniel) (Entered: 12/13/2022) (3) |
| Dec 13, 2022 | 9 | SUMMONS Returned Executed as to Viatris Inc. served on 12/8/2022. (Higginbotham, Daniel) (Entered: 12/13/2022) (3) |
| Sep 23, 2022 | 6 | NOTICE of Appearance by William J O'Brien on behalf of Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., Viatris Inc. (O'Brien, William) (Entered: 09/23/2022) (2) |
| Sep 10, 2022 | 5 | REPORT to USPTO on the filing or determination of an action regarding re 1 Complaint. (Copy Patent/Trademark Office) (dk) (Entered: 09/10/2022) (1) |
| Sep 9, 2022 | 1 | Complaint* (1) |
| Sep 9, 2022 | 2 | SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA) filed by H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd. (dk) (Entered: 09/10/2022) (1) |
| Sep 9, 2022 | 3 | Corporate Disclosure Statement by Otsuka Pharmaceutical Co., Ltd. (dk) (Entered: 09/10/2022) (1) |
| Sep 9, 2022 | 4 | Corporate Disclosure Statement by H. Lundbeck A/S. (dk) (Entered: 09/10/2022) (1) |
